REVB Revelation Biosciences, Inc.
Company Updates ·
James Rolke and Chester Zygmont each received restricted stock awards that vest in four tranches tied to market capitalization milestones of $30 million to $120 million.
Revelation reported a net loss of $3.3 million for the quarter and $11.5 million in cash at June 30, 2026, which it says can fund operations through the first quarter of 2027.
The board adopted a rights plan on July 10, 2026 and declared a dividend of one right per share, payable to stockholders of record on July 21, 2026.
The amended agreements raise change-in-control severance and set a three-year initial term, and the board amended the bylaws on proxy nominations, the definition of Cause and emergency succession.
Cash stood at $14.1 million on March 31, 2026, which the company says covers operations through the first quarter of 2027.
Holders of 13,065,000 Class H warrants agreed to exercise at $2.20 per share and receive 13,065,000 new Class I warrants in a private placement. Roth Capital Partners advised.
Revelation Biosciences said on September 11, 2025 that holders will exercise warrants for up to 4,355,000 shares at $2.20 each, about $9.6 million in gross proceeds. In return they receive new Class I warrants for up to 13,065,000 shares, which cannot be exercised until stockholders approve them.
The Nasdaq Hearings Panel kept the stock listed on two conditions: a reverse stock split by January 31, 2025 and a $1.00 close for ten straight trading days by February 14, 2025. The panel confirmed the equity deficiency is cured.
Revelation Biosciences, Inc. is a clinical-stage life science company focused on rebalancing inflammation with Gemini, its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 agonist. Its lead programs focus on kidney disorders. GEM-AKI is being evaluated as a treatment for acute kidney injury, where the text says the only current treatment is supportive care and renal replacement therapy. The company met with the FDA at the end of 2025 and agreed on a single Phase 2/3 adaptive design study with a primary composite endpoint of death and/or dialysis, to support a new drug application. GEM-CKD is being evaluated as a long-term treatment for chronic kidney disease, and the company plans preclinical toxicology studies in 2026 to support a repeat-dose Phase 2 study. The company may also pursue out-licensing and academic collaborations for Gemini in other conditions. Revelation is based in San Diego, California, and its stock is listed on Nasdaq under the ticker REVB.
| Product or program | What it is | Stage |
|---|---|---|
| GEM-AKI (Gemini) | Gemini formulation for acute kidney injury | Phase 2/3 adaptive design study agreed with FDA; to start as soon as feasible |
| GEM-CKD (Gemini) | Gemini formulation for chronic kidney disease | Preclinical toxicology studies planned for 2026 before a repeat-dose Phase 2 study |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $4.1 million | $3.5 million |
| Net income (loss) | -$8.9 million | -$15.0 million |
| Cash from operations | -$8.3 million | -$18.3 million |
| Cash and equivalents | $10.7 million | $6.5 million |
Our latest story on this, dated Jan 7, 2025: "Nasdaq panel keeps Revelation Biosciences listed on condition of reverse stock split". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 15, 2025: "Revelation Biosciences gets $9.6 million gross proceeds in warrant inducement deal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 7, 2025: "Nasdaq panel keeps Revelation Biosciences listed on condition of reverse stock split". The story links the filing or release it is based on. Read the story.
Revelation Biosciences, Inc. trades under the ticker REVB on NASDAQ.
Revelation Biosciences, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Revelation Biosciences, Inc. is 1810560. Its filings are on SEC EDGAR.
3,983,416 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Revelation Biosciences, Inc. under United States.
Our directory classifies Revelation Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Revelation Biosciences, Inc. is US76135L8871.
aibio.space lists Revelation Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Revelation Biosciences, Inc. is a clinical-stage life science company focused on rebalancing inflammation with Gemini, its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 agonist. Its lead programs focus on kidney disorders.
GEM-AKI (Gemini): Gemini formulation for acute kidney injury Stage: Phase 2/3 adaptive design study agreed with FDA; to start as soon as feasible.
GEM-CKD (Gemini): Gemini formulation for chronic kidney disease Stage: Preclinical toxicology studies planned for 2026 before a repeat-dose Phase 2 study.
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,3.03,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.03,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio